Stephen V Liu, Director of Thoracic Oncology, Chief of the Division of Hematology and Oncology, and Associate Professor at Georgetown Lombardi Comprehensive Cancer Center, shared a post on shared a post on X:
“Phase I results for JYP0322, next gen ROS1 inhibitor Cancer Cell look promising. In 89 pts with NSCLC, RR 95.7% in TKI naive, 57.1% after ≥2 prior TKIs, and 77.8% with acquired ROS1 G2032R resistance mutation. Intracranial RR 55.6%. Low TRK toxicities.”
Title: JYP0322, a highly selective and brain-penetrant ROS1 inhibitor, overcomes ROS1G2032R resistance mutation in NSCLC: The first-in-human phase 1 trial
Authors: Yuxiang Ma, Jinhui Xue1,Fangfang Gao2, Yunpeng Yang1, Yuanyuan Zhao, Linlin Wang, Zhangzhou Huang, Chunjiao Wu, Yongzhong Luo, Juan Li, Jian Fang, Zhengbo Song, Yongsheng Li, Huiwen Ma, Qinxiang Guo, Tienan Yi, Xiting Liu, Zhihua Liu, Jianya Zhou, Xiaorong Dong, Qitao Yu, Jianbo He, Liuzhong Yang, Wenfeng Fang, Yuping Sun, Yaling Qi, Jing Lv, Zhen Ge, Binyan Xia, Lei Li, Wei Wang, Yan Huang, Li Zhang, Hongyun Zhao.
Other articles featuring Stephen V Liu on OncoDaily.
